search
Back to results

Clinical Investigation of Omega Refractive Capsule, Model VI (ORCVI)

Primary Purpose

Cataract

Status
Active
Phase
Not Applicable
Locations
Costa Rica
Study Type
Interventional
Intervention
Omega Refractive Capsule with an FDA approved Intraocular Lens
FDA approved Intraocular Lens
Sponsored by
Omega Ophthalmics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cataract

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 40 years of age or older at the time of surgery diagnosed with bilateral cataracts
  • Able to understand and sign an informed consent
  • Willing and able to complete all study visits and assessments required for the study
  • Calculated lens power within the available range
  • Corrected distance visual acuity is equal to or worse than 20/40 in each eye with or without a glare source present
  • Bilateral cataracts eligible for extraction by phacoemulsification and capsular bag fixated IOL implantation
  • Potential postop visual acuity of 20/25 or better in the judgment of the surgeon
  • Preoperative corneal astigmatism of 4.0 D or less with normal corneal topography
  • Clear intraocular media other than cataract
  • Preop endothelial cell density of 2000 cells/mm2 or more

Exclusion Criteria:

  • Subject's best corrected vision is light perception or no light perception in either eye
  • Cataract opacification preventing adequate Binocular Indirect Ophthalmoscopic retinal and macular examination.
  • Orbital abnormalities, such as thyroid related orbitopathy, causing significant exophthalmos.
  • Eyelid abnormalities causing lagophthalmos.
  • Significant anterior blepharitis or meibomian gland dysfunction
  • Corneal abnormalities or conditions, other than regular topographic corneal astigmatism
  • Krukenburg's spindle (linear pigmentary deposits on the corneal endothelium)
  • Abnormalities of the iris including trans-illumination defects
  • Pupil abnormalities (abnormally shaped, fixed or non-reactive)
  • Pharmacologic dilation less than 7 mm
  • Axial length <22.5mm
  • Lens thickness <4.1 mm
  • Anterior chamber depth <2.5mm
  • Prior ocular surgery
  • Epiretinal membrane
  • Macular edema
  • Retinal tears including operculated holes
  • Amblyopia
  • Glaucoma of any kind
  • Pseudoexfoliation syndrome
  • History of uveitis/iritis
  • Diabetic retinopathy
  • Acute, chronic or uncontrolled systemic or ocular disease that may confound the results of the study (including rheumatologic conditions such as Rheumatoid arthritis, ankylosing spondyliltis, Sjögren's syndrome, and neurologic conditions such as optic neuritis or multiple sclerosis).
  • Prior or anticipated use of tamsulosin or silodosin (e.g., Flomax®, Flomaxtra®, Rapaflo®) or similar medications
  • Average Keratometry <38D or > 48D by topography
  • Any pathology of the zonules including evidence of zonular weakness, zonular instability, zonular damage, or coloboma effecting zonules.
  • History of ocular trauma
  • Pregnant, lactating, or has another condition with associated fluctuation of hormones that could lead to refractive changes

Sites / Locations

  • Clinica 20/20

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Study Eye

Control Eye

Arm Description

study eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens.

Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).

Outcomes

Primary Outcome Measures

Absence of fusion of peripheral anterior and posterior capsule
slit lamp exam assessment

Secondary Outcome Measures

Full Information

First Posted
September 15, 2020
Last Updated
March 27, 2023
Sponsor
Omega Ophthalmics
search

1. Study Identification

Unique Protocol Identification Number
NCT04574115
Brief Title
Clinical Investigation of Omega Refractive Capsule, Model VI
Acronym
ORCVI
Official Title
Clinical Investigation of Omega Refractive Capsule, Model VI in Combination With a Commercially Available, FDA Approved Monofocal or Toric Intraocular Lens
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 6, 2021 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Omega Ophthalmics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to evaluate the safety and effectiveness of the investigational Omega Refractive Capsule (model VI)
Detailed Description
This study is a prospective, interventional, randomized, controlled, paired eye, subject-masked design. Subjects will be randomly assigned to which eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens. Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This study is a prospective, interventional, randomized, controlled, paired eye, subject-masked design. Subjects will be randomly assigned to which eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens. Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).
Masking
Participant
Masking Description
subject masked to treatment
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Study Eye
Arm Type
Experimental
Arm Description
study eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens.
Arm Title
Control Eye
Arm Type
Active Comparator
Arm Description
Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule).
Intervention Type
Device
Intervention Name(s)
Omega Refractive Capsule with an FDA approved Intraocular Lens
Intervention Description
Omega refractive capsule in conjunction with an FDA approved Intraocular Lens
Intervention Type
Device
Intervention Name(s)
FDA approved Intraocular Lens
Intervention Description
FDA approved Intraocular Lens
Primary Outcome Measure Information:
Title
Absence of fusion of peripheral anterior and posterior capsule
Description
slit lamp exam assessment
Time Frame
6 Month Postoperative Visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 40 years of age or older at the time of surgery diagnosed with bilateral cataracts Able to understand and sign an informed consent Willing and able to complete all study visits and assessments required for the study Calculated lens power within the available range Corrected distance visual acuity is equal to or worse than 20/40 in each eye with or without a glare source present Bilateral cataracts eligible for extraction by phacoemulsification and capsular bag fixated IOL implantation Potential postop visual acuity of 20/25 or better in the judgment of the surgeon Preoperative corneal astigmatism of 4.0 D or less with normal corneal topography Clear intraocular media other than cataract Preop endothelial cell density of 2000 cells/mm2 or more Exclusion Criteria: Subject's best corrected vision is light perception or no light perception in either eye Cataract opacification preventing adequate Binocular Indirect Ophthalmoscopic retinal and macular examination. Orbital abnormalities, such as thyroid related orbitopathy, causing significant exophthalmos. Eyelid abnormalities causing lagophthalmos. Significant anterior blepharitis or meibomian gland dysfunction Corneal abnormalities or conditions, other than regular topographic corneal astigmatism Krukenburg's spindle (linear pigmentary deposits on the corneal endothelium) Abnormalities of the iris including trans-illumination defects Pupil abnormalities (abnormally shaped, fixed or non-reactive) Pharmacologic dilation less than 7 mm Axial length <22.5mm Lens thickness <4.1 mm Anterior chamber depth <2.5mm Prior ocular surgery Epiretinal membrane Macular edema Retinal tears including operculated holes Amblyopia Glaucoma of any kind Pseudoexfoliation syndrome History of uveitis/iritis Diabetic retinopathy Acute, chronic or uncontrolled systemic or ocular disease that may confound the results of the study (including rheumatologic conditions such as Rheumatoid arthritis, ankylosing spondyliltis, Sjögren's syndrome, and neurologic conditions such as optic neuritis or multiple sclerosis). Prior or anticipated use of tamsulosin or silodosin (e.g., Flomax®, Flomaxtra®, Rapaflo®) or similar medications Average Keratometry <38D or > 48D by topography Any pathology of the zonules including evidence of zonular weakness, zonular instability, zonular damage, or coloboma effecting zonules. History of ocular trauma Pregnant, lactating, or has another condition with associated fluctuation of hormones that could lead to refractive changes
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claudio Orlich, MD
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinica 20/20
City
San José
Country
Costa Rica

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clinical Investigation of Omega Refractive Capsule, Model VI

We'll reach out to this number within 24 hrs